Study | Year | Country | n | TNM or risk group | RT | Design | Schedule | ADT | Outcomes |
---|---|---|---|---|---|---|---|---|---|

Aluwini et al | 2015–2016 | Netherlands | 410 | T_{1b}-T_{4}N_{X-0}M_{X-0}intermediate- to high-risk | Most IMRT | Hypofractionated versus conventional | 64.6Gy (19 fractions within 6.5wks) | Yes | OS, BF acute and late adverse events |

410 | 78Gy (39 fractions within 8wks) | ||||||||

Arcangeli et al | 2010–2017 | Italy | 83 | ≥T_{2c}, Gleason ≥7PSA ≥20ng/ml high-risk | 3D-CRT | Hypofractionated versus conventional | 62Gy (20 fractions of 3.1Gy, 5wks) | Yes | OS, BF, PCaSS acute and late adverse events |

85 | 80Gy (40 fractions of 2Gy, 8wks) | ||||||||

Pollack et al | 2007–2013 | US | 154 | T_{1}-T_{3}, Gleason ≥5intermediate- to high-risk | IMRT | Hypofractionated versus conventional | 70.2Gy (26 fractions of 2.7Gy) | Yes | OS, BF late adverse event |

153 | 76Gy (38 fractions of 2Gy) | ||||||||

Marzi et al | 2009 | Italy | 57 | ≥T_{2c}, Gleason7-10PSA>10ng/ml high-risk | 3D-CRT | Hypofractionated versus conventional | 62Gy (20 fractions of 3.1Gy) | Yes | late adverse event |

57 | 80Gy (40 fractions of 2Gy) | ||||||||

Strigary et al | 2009 | Italy | 80 | localized prostate cancer high-risk | 3D-CRT | Hypofractionated versus conventional | 62Gy (20 fractions of 3.1Gy) | Yes | acute adverse event |

52 | 56Gy (16 fractions of 3.5Gy) | ||||||||

80Gy (40 fractions of 2Gy, 8wks) | |||||||||

80 | |||||||||

Catton et al | 2017 | Canada | 608 | intermediate-risk | IMRT | Hypofractionated versus conventional | 60Gy (20 fractions of 3Gy) | Yes | BF, PCaSS acute and late adverse events |

Australia | |||||||||

France | 598 | 78Gy (39 fractions of 2Gy) |